The Fast-Track^® T-Cell innovative platform leverages 15 years of experience by CIML/CIPHE, underscoring JC Discovery^® position as a leader in the field. We aim to accelerate the selection of lead T-cell products and models for clinical translation by:
‍
- Gene-editing and engineering of therapeutic T-cells.
- In vivo preclinical evaluation of anti-cancer adoptive T-cell therapy including CAR-T cells using the suite of immuno-deficient and humanized mouse models developed by Janvier Labs.
- Deciphering the mode of action of therapeutic compounds targeting pathogenic human T-cells using advanced interactomics.
- Developing genetically enhanced CAR-T cells with improved effector functions and durability.

We intervene on the "validation target" segment of the discovery process via the design of new preclinical models with high predictive value for clinical safety and efficacy.